In this video, Aimee Tharaldson, PharmD, Senior Clinical Consultant, Emerging Therapeutics at Express Scripts, Inc, says that the increasing of specialty medication approvals impacts both patients and payers.
In this video, Aimee Tharaldson, PharmD, Senior Clinical Consultant, Emerging Therapeutics at Express Scripts, says that the increasing of specialty medication approvals impacts both patients and payers.
With the increased approvals, patients are now finding themselves with more medication options. Payers, however, are concerned with the increase due to the cost of the specialty drugs.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More